Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genta has reported that Richard Moran, senior vice-president and CFO has indicated his intention to retire from the company effective February 29, 2008.
Subscribe to our email newsletter
Upon Mr. Moran’s retirement, Gary Siegel, currently vice president of finance, will assume the roles of principal accounting officer and principal financial officer. Mr. Siegel has served the company for the past five years in financial roles of increasing responsibility. Mr. Moran has agreed to serve as a consultant to the company to ensure a smooth transition during this period.
Genta also announced the appointment of Michael Yoshitsu as vice president, global business development. In this capacity, Dr. Yoshitsu will lead activities related to in-licensing of new products, as well as partnering negotiations for the company’s existing products, including Genasense (oblimersen sodium) injection, Ganite (gallium nitrate injection), and G4544, a new oral drug for accelerated bone loss.
Raymond Warrell, Jr., chairman and CEO of Genta, said: “We are pleased that Dr. Yoshitsu has agreed to join us in leading our key business development activities that are currently active on a number of fronts.”